Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Leases (2021 - 2025)

Historic Current Leases for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $4.7 million.

  • Lyra Therapeutics' Current Leases rose 1701.22% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 1701.22%. This contributed to the annual value of $4.1 million for FY2024, which is 2416.27% down from last year.
  • As of Q3 2025, Lyra Therapeutics' Current Leases stood at $4.7 million, which was up 1701.22% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' Current Leases peaked at $5.4 million during Q4 2023, and registered a low of $654000.0 during Q3 2022.
  • For the 5-year period, Lyra Therapeutics' Current Leases averaged around $2.6 million, with its median value being $1.7 million (2023).
  • Per our database at Business Quant, Lyra Therapeutics' Current Leases tumbled by 3783.27% in 2022 and then soared by 25080.7% in 2023.
  • Over the past 5 years, Lyra Therapeutics' Current Leases (Quarter) stood at $1.1 million in 2021, then skyrocketed by 44.23% to $1.5 million in 2022, then surged by 250.81% to $5.4 million in 2023, then dropped by 24.16% to $4.1 million in 2024, then rose by 13.66% to $4.7 million in 2025.
  • Its Current Leases stands at $4.7 million for Q3 2025, versus $4.6 million for Q2 2025 and $4.2 million for Q1 2025.